University of north carolina - tbcrc evolutionary clinical trial for novel biomarker-driven therapies (evolve-BDT) - adapt program
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042590009
- Awardee
-
University Of North Carolina At Chapel Hill UEI D3LHU66KBLD5 Part of University Of North Carolina System Office
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $13,292,510
Award facts
- Contract value 47% obligated
-
- $13,292,510.00 Current, with exercised options
- $28,120,143.00 Potential, with all options
- Completion date 24% complete
-
- Current, with exercised options
- Potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- Competition
- Competed Program Solicitation
- Pricing
- Other
- Place of performance
- Chapel Hill, NC 27599, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $13,292,510 |
About this award
The National Institutes of Health awarded an Other Transaction Agreement to the University of North Carolina at Chapel Hill for the TBCRC Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE-BDT), seated within the ADAPT Program, with a ceiling value of $28,120,143 and an award date of May 20, 2025.
The agreement supports a biomarker-driven adaptive clinical trial framework designed to evaluate novel therapeutic approaches in oncology. Performance occurs in Chapel Hill, North Carolina, with an ultimate completion date of May 19, 2031. This OTA sits outside the FAR regulatory framework, providing the funding agency and awardee flexibility in prototype development and execution structures typical of NIH-supported translational research efforts.
The University of North Carolina at Chapel Hill, operating through its Office of Sponsored Research, is a non-profit research institution with substantial federal biomedical research infrastructure. The institution's recent federal portfolio spans cancer therapeutics, biomarker development, and translational oncology—domains directly aligned with this clinical trial effort. UNC-Chapel Hill holds established relationships with the National Cancer Institute and related NIH institutes, with combined recent potential value exceeding $200 million in cancer biology and therapeutics research.
Quick answers
Who was awarded contract 140D042590009?
140D042590009 was awarded to University Of North Carolina At Chapel Hill by Interior Business Center (Office of Policy Management and Budget) on May 20, 2025.
How much is contract 140D042590009 worth?
The government has obligated $13,292,510 on 140D042590009. Its potential value, with all options, is $28,120,143.
Which agency awarded contract 140D042590009?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042590009, with funding from National Institutes of Health (Department of Health and Human Services).
Was contract 140D042590009 competed?
The extent of competition for 140D042590009 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award